MWNA
IMVT icon

Marshall Wace North America’s Immunovant IMVT Stock Holding History

Marshall Wace North America’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$105K Sell
11,994
-151,962
-93% -$1.37M ﹤0.01% 1361
2021
Q2 		$1.73M Buy
+163,956
New +$2.29M 0.01% 849

Other funds holding IMVT

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace North America's IMVT Position: Q3 2021 in Review

Marshall Wace North America reduced its Immunovant (IMVT) stake by 93% in Q3 2021, selling an estimated $1.37M and leaving 11,994 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #1361.

Marshall Wace North America first reported a position in IMVT in Q2 2021 and has held it in 2 quarters since. The position peaked at $1.73M in Q2 2021. 119 funds tracked by Wall St. Rank hold IMVT as of Q3 2021.

  • Marshall Wace North America held 11,994 shares of Immunovant worth $105K as of Q3 2021.
  • Marshall Wace North America sold 151,962 Immunovant shares in Q3 2021, an estimated $1.37M.
  • Immunovant made up ﹤0.01% of Marshall Wace North America's portfolio in Q3 2021, its #1361 holding.
  • Marshall Wace North America first reported a position in Immunovant in Q2 2021 and has held it in 2 quarters since.
  • Marshall Wace North America's Immunovant position peaked at $1.73M in Q2 2021.
  • 119 funds tracked by Wall St. Rank held Immunovant as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.